These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 16108961)

  • 1. Treatment persistency with rivastigmine and donepezil in a large state medicaid program.
    Singh G; Thomas SK; Arcona S; Lingala V; Mithal A
    J Am Geriatr Soc; 2005 Jul; 53(7):1269-70. PubMed ID: 16108961
    [No Abstract]   [Full Text] [Related]  

  • 2. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
    Aguglia E; Onor ML; Saina M; Maso E
    Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
    Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
    Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
    Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN
    Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholinesterase inhibitor treatment and urinary incontinence in Alzheimer's disease.
    Starr JM
    J Am Geriatr Soc; 2007 May; 55(5):800-1. PubMed ID: 17493206
    [No Abstract]   [Full Text] [Related]  

  • 6. Adherence to cholinesterase inhibitors in patients with Alzheimer's disease.
    Blais L; Kettani FZ; Perreault S; Leroux JC; Forget A; Kergoat MJ
    J Am Geriatr Soc; 2009 Feb; 57(2):366-8. PubMed ID: 19207161
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
    Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
    Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholinesterase inhibitors in Alzheimer's disease: donepezil or rivastigmine?
    Sharma JC
    Int J Clin Pract; 2002; 56(6):414-5. PubMed ID: 12166537
    [No Abstract]   [Full Text] [Related]  

  • 9. Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease.
    Sadowsky CH; Dengiz A; Olin JT; Koumaras B; Meng X; Brannan S;
    Am J Alzheimers Dis Other Demen; 2009; 24(3):267-75. PubMed ID: 19293130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug-cholinesterase-inhibitors persistence patterns in treated patients with dementia of Alzheimer type: retrospective comparative analysis of donepezil, rivastigmine and galantamine].
    Sicras A; Rejas-Gutiérrez J
    Rev Neurol; 2004 Aug 16-31; 39(4):312-6. PubMed ID: 15340887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
    Prescrire Int; 2007 Oct; 16(91):197-8. PubMed ID: 17926835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of donepezil and rivastigmine.
    Grossberg G
    Int J Clin Pract; 2003; 57(1):70-1; author reply 71. PubMed ID: 12587950
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparing treatment effects in a clinical sample of patients with probable Alzheimer's disease treated with two different cholinesterase inhibitors.
    Caffarra P; Vezzadini G; Copelli S; Dieci F; Messa G; Nonis E; Venneri A
    Acta Biomed; 2007; 78(1):16-21. PubMed ID: 17687812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case history illustrating how extended release cholinesterase inhibitors could improve management of Alzheimer's disease.
    Alisky JM
    J Alzheimers Dis; 2003 Dec; 5(6):477-8. PubMed ID: 14757938
    [No Abstract]   [Full Text] [Related]  

  • 15. No donepezil discontinuation effect in patients with Alzheimer's disease who were switched to rivastigmine after failing to benefit from donepezil treatment.
    Auriacombe S; Pere JJ;
    Curr Med Res Opin; 2003; 19(8):715-7. PubMed ID: 14687442
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings.
    Mauskopf JA; Paramore C; Lee WC; Snyder EH
    J Manag Care Pharm; 2005 Apr; 11(3):231-51. PubMed ID: 15804207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
    Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of journal advertisements on prescribers of cholinesterase inhibitors.
    Sauer J; Howard R
    Int J Geriatr Psychiatry; 2002 Oct; 17(10):976-8. PubMed ID: 12325061
    [No Abstract]   [Full Text] [Related]  

  • 19. Advertisements for donepezil (Aricept) in the BMJ. Local committee has declined to approve NHS hospital prescription of donepezil.
    Wagner N
    BMJ; 1997 May; 314(7093):1555-6. PubMed ID: 9183223
    [No Abstract]   [Full Text] [Related]  

  • 20. Beneficial effect of cholinesterase inhibitor medications on recognition memory performance in mild to moderate Alzheimer's disease: preliminary findings.
    Crowell TA; Paramadevan J; Abdullah L; Mullan M
    J Geriatr Psychiatry Neurol; 2006 Mar; 19(1):13-5. PubMed ID: 16449754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.